Fentanyl

# Research Output: Fentanyl

## Chemical Identity

**Verified from PubChem (CID 3345) and IUPHAR [Ref 40]:**

- **Molecular formula:** C₂₂H₂₈N₂O
- **Molecular weight:** 336.5 g/mol
- **CAS number:** 437-38-7
- **PubChem CID:** 3345
- **IUPAC name:** N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (confirmed from PubChem API)
- **InChIKey:** PJMPHNIQZUBGLI-UHFFFAOYSA-N
- **SMILES:** CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1 (from published literature; not confirmed via API — flag below)
- **Physical state:** White granular or crystalline powder [Ref 39]
- **Melting point:** 83–84°C [Ref 45]
- **Water solubility:** 0.74 mg/mL at neutral pH, 35°C; 0.20 mg/mL at 25°C [Ref 45]
- **logP (experimental):** 4.05 [Ref 45]
- **Octanol:water partition coefficient:** >700 [Ref 1]
- **pKa:** 8.43 (piperidine nitrogen) [Ref 45]

**Notes on brief seed data:** The brief correctly lists IUPAC name and InChIKey. Molecular formula, weight, and PubChem CID were absent and are now confirmed. SMILES field was blank; the canonical SMILES is provided above but flagged for independent verification.

**Stereochemistry:** Fentanyl possesses one chiral center at C-4 of the piperidine ring. The pharmaceutical product is marketed as a racemate. The (R)-enantiomer is considered more pharmacologically active at MOR. Fentanyl analogs with multiple chiral centers (e.g., cis(+)-3-methylfentanyl) show dramatically enhanced potency — cis(+)-3-methylfentanyl is 6,684× more potent than morphine in animal studies [Ref 39]. The brief does not address stereochemistry; no dedicated human clinical study of fentanyl enantiomer potency comparison was found.

---

## Pharmacology

### Receptor Binding

Fentanyl is a full agonist at the μ-opioid receptor (MOR), its primary pharmacological target. Binding affinity data from the IUPHAR/BPS Guide to Pharmacology [Ref 40]:

- **Human MOR:** pKi 8.28–10.29 (Ki = **0.05–5.23 nM**); IC₅₀ 1.3–10.72 nM
- **Human δ-opioid receptor (DOR):** Ki = 570–1,035 nM — substantially weaker; not clinically significant
- **Human κ-opioid receptor (KOR):** Ki ≈ 197 nM — moderate affinity; Gharagozlou et al. (2006 [Ref 34]) found fentanyl demonstrated the **highest intrinsic activity** among tested opioids at mouse KOR in HEK cells. This KOR activity is pharmacologically notable but not the primary driver of therapeutic or adverse effects.

The wide range in Ki values (0.007–214 nM across all studies) reflects experimental variability in radioligand, tissue, and species selection. IUPHAR human data represents the most methodologically standardized source [Ref 40].

**Efficacy at MOR:** Fentanyl is a high-efficacy full MOR agonist. Selley et al. (1997 [Ref 5]) showed DAMGO was the most efficacious agonist, followed by fentanyl = morphine >> buprenorphine in rat thalamus and SK-N-SH cells. Emmerson et al. (1996 [Ref 4]) similarly ranked fentanyl among full efficacy agonists (etonitazene = sufentanil = DAMGO = fentanyl > morphine) in C6 glioma cells expressing rat MOR.

**Potency relative to morphine:** At least 80–100× more potent than morphine clinically; 470× in animal studies [Ref 39]. Sufentanil (Ki ~0.034 nM [Ref 4]) is significantly more potent than fentanyl.

### Molecular Mechanism of MOR Binding

Vo et al. (2021 [Ref 2]) elucidated fentanyl's MOR binding mechanism using molecular simulation. In addition to the canonical salt-bridge binding mode common to morphinan opiates, fentanyl can adopt a **secondary "deep pocket" binding mode** in which it forms a stable hydrogen bond with the conserved His297⁶·⁵² when this residue adopts a neutral HID tautomer. This deep insertion involves enhanced hydrophobic contacts with transmembrane helix 6 (TM6) and lowers the fentanyl-MOR residence time to approximately τ ≈ 38 s in this configuration (Mahinthichaichan et al. 2021 [Ref 3]). The deep binding mode may be biologically relevant and has implications for the challenge of naloxone displacement (see Harm Reduction).

O'Brien et al. (2024 [Ref 6]) identified a negative allosteric modulator (NAM) site on MOR's extracellular vestibule that enhances naloxone affinity and cooperatively inhibits fentanyl-induced signaling — providing structural rationale for next-generation reversal strategies.

### Pharmacokinetics

**Lipophilicity and CNS penetration:** Fentanyl's high lipophilicity (logP 4.05 [Ref 45]; octanol:water >700 [Ref 1]) enables rapid CNS penetration. Blood-brain plasma transfer half-life is 4.7–6.6 min [Ref 1]. This rapid central nervous system equilibration underlies both the fast analgesic onset and reinforcement potential.

**Metabolism:** Fentanyl undergoes N-dealkylation by **CYP3A4** to the inactive metabolite **norfentanyl** as the primary pathway [Ref 24]. CYP3A5 genotype affects plasma fentanyl concentrations in cancer patients (Ishida et al. 2016). Geist et al. (2019 [Ref 19]) reported that CYP3A activity had only a weak correlation with fentanyl clearance in palliative patients (mean total clearance 75.5 L/h), suggesting that in vivo clearance is not entirely CYP3A-dependent. Ibrahim et al. (2003 [Ref 38]) established that fentanyl is a **high-extraction** hepatic drug; this means it is less susceptible to changes in enzyme activity (compared to low-extraction alfentanil) but more sensitive to changes in hepatic blood flow.

**Bioavailability by route:**
- Oral (swallowed): ~30% (extensive first-pass CYP3A metabolism) [Ref 1]
- Oral transmucosal/sublingual: 50–90%; Tmax ~20 min (range 20–180 min) [Ref 1]
- Intranasal: 89% (pectin-containing formulations, e.g., PecFent/Lazanda); Tmax ~12–21 min [Ref 17]
- Transdermal: ~44%; Tmax ~41–45 h; elimination t½ from patch ~21–22 h [Ref 20]; patches deliver fentanyl at approximately constant zero-order rate for 72 h [Ref 1]

**IV pharmacokinetics (Mather 1983 [Ref 36]; considered the foundational PK review):**
- Volume of distribution (area): 60–300 L (~4 L/kg estimated); wide inter-individual variability
- Terminal elimination half-life: 1.5–6 hours (up to 15 hours in geriatric patients)
- Total body clearance: 0.4–1.5 L/min
- Protein binding: ~80–85% (primarily alpha-1-acid glycoprotein; albumin secondary) [Ref 24]
- Duration of action after single IV dose: redistribution-limited, analogous to thiopentone

**Redistribution phenomenon:** Multiple or large IV doses lead to accumulation in peripheral compartments (muscle, fat) and delayed redistribution, producing prolonged respiratory depression or secondary peaks in plasma concentration — the mechanism underlying reported post-anesthetic re-narcotization (Mather 1983 [Ref 36]).

---

## History

Fentanyl was synthesized in **1960** by **Paul Janssen** at Janssen Pharmaceutica (Belgium), as confirmed by Stanley (1992 [Ref 7]) and Lötsch et al. (2013 [Ref 1]). Janssen was investigating structure-activity relationships in synthetic opioids and designed fentanyl's anilidopiperidine scaffold specifically to achieve high MOR selectivity. The 1960 synthesis "laid the foundation for a better understanding of the structure-activity relationships of narcotic analgesics" (Stanley 1992 [Ref 7]).

Fentanyl was introduced to **US clinical anesthesia in the early 1970s** (Stanley 1992 [Ref 7]; Torralva & Janowsky 2019 [Ref 16]), where it revolutionized cardiac surgery by combining profound analgesia with hemodynamic stability unlike morphine. High-dose fentanyl anesthesia (50–100 μg/kg with 100% oxygen) was adopted for mitral valve and coronary artery surgery, with cardiovascular changes at induction doses of 8–30 μg/kg limited to small decreases in heart rate and blood pressure [Ref 7].

Fentanyl was placed under **Schedule I of the UN Single Convention on Narcotic Drugs** (1961) in **1964** [Ref 39]. In the United States, it was classified as a DEA **Schedule II** controlled substance under the Controlled Substances Act of 1970. Commercial pharmaceutical preparations (Sublimaze, Duragesic transdermal patch, Actiq oral transmucosal lozenge, etc.) were approved by the FDA for anesthesia and pain management.

**The illicit fentanyl crisis:** From 2013 onward, illicitly manufactured fentanyl (IMF) began driving a catastrophic increase in overdose deaths. Synthetic opioid-involved death rates increased **1,040%** from 2013 to 2019 in the US (Mattson et al. 2021 [Ref 29]). By 2017, 47,600 of 70,237 drug overdose deaths (67.8%) involved an opioid, primarily driven by IMF (Scholl et al. 2018 [Ref 28]). CDC declared fentanyl the deadliest drug in America in December 2018 [Ref 16]. Beginning around 2018–2019, fentanyl analogs and xylazine adulterant began further complicating the epidemic.

**Fentanyl-related substances (FRS):** DEA issued a temporary class-wide Schedule I order for FRS (as a class) in February 2018, subsequently extended multiple times (most recently through September 2025) [Ref 30].

---

## Subjective Effects

**Controlled human study data:** Baylon et al. (2000 [Ref 43]) conducted a randomized, double-blind crossover study comparing fentanyl and remifentanil in 12 recreational opioid users. Fentanyl produced statistically significant responses on:
- **"High" VAS** (peak effect; greater than remifentanil)
- **"Liking" VAS**
- **"Good Effects" VAS**
- **Cole/ARCI Abuse Potential subscale**

Fentanyl's area-under-the-response-curve (AUC) was generally larger than remifentanil's, reflecting its longer duration. The brief's effects taxonomy is consistent with the established MOR agonist profile. Additional controlled data on specific subjective effects categories derives from the pharmacodynamic literature rather than dedicated human phenomenology studies.

**Effects taxonomy (from brief — consistent with literature):**
- **Perception:** Dreaming enhancement, double vision
- **Body:** Pupil constriction (miosis — classic opioid sign), pain suppression, respiratory depression, sexual arousal suppression, appetite suppression, tactile euphoria, increased urination, excessive sweating, spontaneous body sensations, abnormal heartbeat, sedation, constipation
- **Thinking:** Compulsive redosing urge, cognitive euphoria
- **Feeling:** Anxiety suppression

**Duration data (from brief — consistent with PK literature):**
- Sublingual/insufflated onset: 15–30 min; total: 1–4 hours
- Transdermal onset: 2–4 hours (due to slow absorption through skin); total: 48–72 hours

---

## Safety & Toxicity

### Acute Toxicity

The primary mechanism of fentanyl overdose death is **opioid-induced respiratory depression (OIRD)** — suppression of respiratory drive through brainstem MOR agonism, primarily via the preBötzinger complex inspiratory rhythm generator (Rai et al. 2025 [Ref 42]) and chemosensitive retrotrapezoid nucleus (RTN) neurons (Moreira et al. 2025 [Ref 14]).

The brief cites an estimated lethal dose of **~2 mg in opioid-naïve individuals** and approximately **80,000 OIRD deaths/year in the US**. The CDC MMWR data (Scholl et al. 2018 [Ref 28]; Mattson et al. 2021 [Ref 29]) confirms the scale of synthetic opioid mortality, though the precise annual figure has varied: 36,359 synthetic opioid deaths in 2019 [Ref 29], with the 80,000 figure plausible for more recent years with fentanyl analogs and polysubstance deaths included. The specific 2 mg lethal dose figure could not be verified against a specific published source and is flagged below.

**Therapeutic serum concentrations (EUDA [Ref 39]):**
- Analgesia: 1–2 ng/mL
- Anesthesia: 10–20 ng/mL
- Fatal overdose cases: typically ≥7 ng/mL

**Tolerance to OIRD vs. analgesia:** The brief states that tolerance to analgesia develops faster than tolerance to respiratory depression, creating escalating overdose risk. This differential tolerance mechanism is supported by the general opioid tolerance literature. Rai et al. (2025 [Ref 42]) demonstrated in mice that repeated fentanyl use produced divergent ventilatory responses — 77% of mice showed adaptive (more resistant) ventilatory responses after 5 days, while 23% showed no adaptation; the preBötzinger complex was less sensitive to MOR agonism after repeated use. This suggests tolerance to OIRD does develop, but is incomplete and heterogeneous, meaning escalating overdose risk is real.

### Wooden Chest Syndrome (WCS)

WCS — fentanyl-induced skeletal muscle rigidity causing ventilatory failure — is documented in case reports (Rosal et al. 2021 [Ref 10]; Pergolizzi et al. 2021 [Ref 11]) and review literature (Torralva & Janowsky 2019 [Ref 16]; Stanley 1992 [Ref 7]). WCS involves thoracoabdominal rigidity and upper airway closure within a narrow dosing range, making bag-valve-mask ventilation impossible. Torralva & Janowsky (2019 [Ref 16]) propose that WCS involves **α-adrenergic and cholinergic receptor-mediated mechanical failure** distinct from the standard MOR-mediated respiratory rate suppression — which would explain why naloxone (a pure MOR antagonist) may be insufficient to reverse WCS-related respiratory compromise in some cases.

### Redistribution / Delayed Re-narcotization

Mather (1983 [Ref 36]) documented that multiple or large IV doses of fentanyl cause accumulation in peripheral compartments, with subsequent redistribution producing secondary plasma peaks and prolonged respiratory depression. The brief's claim that "delayed re-narcotization from tissue depot redistribution documented in 7.6% of cardiac surgery patients" could not be traced to a specific publication via literature search. The general phenomenon is well-documented [Ref 36]; the 7.6% figure is flagged for editorial verification.

### Organ Toxicity

- **Respiratory system:** Primary target of acute toxicity via OIRD [Refs 14, 42]
- **Cardiovascular:** Fentanyl noted for hemodynamic stability at clinical doses (small decreases in HR and BP); vagal-mediated bradycardia possible; Baertsch (2025) documents xylazine combination causing cardiovascular collapse [Ref 26]
- **Gastrointestinal:** Constipation (MOR agonism in GI tract)
- **CNS:** Chronic use — neurocognitive impairment cited in brief; no specific primary study found in this literature search

---

## Harm Reduction

### Naloxone Reversal

Naloxone is the standard reversal agent for fentanyl OIRD, but the evidence base reveals important limitations:

1. **Higher doses needed for fentanyl vs. heroin:** Saari et al. (2024 [Ref 25]) state that "fentanyl overdoses likely require higher doses of naloxone" than heroin overdoses. van Lemmen et al. (2026 [Ref 13]) confirmed 4 mg intranasal naloxone reverses fentanyl-induced respiratory depression but effectiveness may be incomplete in daily opioid users.

2. **Nalmefene superiority:** Cipriano et al. (2025 [Ref 12]) demonstrated nalmefene 1.5 mg IM by auto-injector achieved faster onset (superiority at 5 min, 10, 15, 20, 30 min), higher magnitude, and longer duration of OIRD reversal compared to naloxone 4 mg IN — relevant given fentanyl's tight receptor binding kinetics.

3. **WCS and naloxone limitations:** Torralva & Janowsky (2019 [Ref 16]) propose that the noradrenergic/cholinergic component of WCS may be unresponsive to naloxone, explaining some field failures.

4. **Gabapentinoid interaction:** Hiranita et al. (2024 [Ref 22]) found gabapentin and pregabalin decrease naloxone potency to antagonize fentanyl — clinically significant given widespread gabapentinoid co-prescribing.

### Buprenorphine as Alternative Reversal

Baehr et al. (2025 [Ref 23]) showed that buprenorphine 3.0 mg/kg reversed fentanyl-induced respiratory depression within 3.5 minutes in rats — comparable to naloxone — supporting consideration of buprenorphine repurposing for overdose reversal.

### Xylazine Adulterant

Xylazine (alpha-2 adrenergic agonist, "tranq") increasingly adulterates the fentanyl supply. Puzovic et al. (2025 [Ref 26]) confirmed additive cardiorespiratory depression with fentanyl-xylazine mixtures and demonstrated naloxone's inadequacy against the xylazine component. Wagner et al. (2023) documented fentanyl contamination in stimulant supplies as well. Naloxone or nalmefene reverses the opioid component but not the xylazine-mediated effects; atipamezole (alpha-2 antagonist) reverses xylazine but combination use causes cardiovascular instability [Ref 26].

### Fentanyl Test Strips (FTS)

FTS are an evidence-based harm reduction tool for detecting fentanyl contamination in drug supplies. Multiple studies document their deployment in emergency departments, syringe service programs, and supervised consumption sites [Refs: PMID 41391444, 41261884, 40578796, 37826988, 36333960].

### CYP3A4 Drug Interactions

- Ketoconazole (strong CYP3A4 inhibitor): Increases fentanyl AUC by 33%, reduces clearance to 78% (Ziesenitz et al. 2015 [Ref 18])
- Ritonavir (potent CYP3A4 inhibitor): Reduces fentanyl clearance and prolongs half-life (Olkkola et al. 1999 [Ref 37])
- Fentanyl itself does not inhibit CYP3A4 [Ref 18]

---

## Tolerance & Dependence

### Tolerance Mechanism

The brief's proposed mechanism is supported by published literature:

- **GRK3-mediated phosphorylation:** Hurlé (2001 [Ref 9]) confirmed that GRK2, GRK3, GRK6, and β-arrestin 2 are involved in short- and long-term adaptive changes in MOR activity. GRK3 expression increased in acutely sufentanil-treated rats; GRK2/6 and β-arrestin 2 upregulated with chronic treatment.
- **β-arrestin recruitment → receptor desensitization/uncoupling from Gi/Go:** Consistent with GRK-mediated phosphorylation of MOR C-terminal serine/threonine residues [Ref 9]
- **Compensatory adenylyl cyclase upregulation:** He et al. (2009) demonstrated that chronic morphine promotes adenylyl cyclase superactivation (cAMP overshoot), a marker of physical dependence; this represents the "compensatory new homeostatic set point" described in the brief.
- **Fentanyl vs. morphine tolerance:** Imai et al. (2006 [Ref not retrieved; PMID 17240843]) found fentanyl-treated mice showed more rapid disappearance of anti-hyperalgesic effect compared to morphine, associated with increased phosphorylated MOR and reduced Rab4-dependent resensitization. This is consistent with the brief's claim that fentanyl's high efficacy drives GRK3-dependent desensitization more effectively than morphine.

### Differential Tolerance (Safety-Critical)

The claim that "tolerance to analgesia develops faster than tolerance to respiratory depression" is a cornerstone of fentanyl's escalating overdose risk profile. This principle is consistent with the differential receptor reserve theory and with repeat-dosing mouse data from Rai et al. (2025 [Ref 42]) showing incomplete tolerance to ventilatory depression in a minority of animals despite multiple exposures. **This claim could not be verified with a single definitive human controlled study and is flagged for editorial review.**

### Cross-Tolerance

Published cross-tolerances (from brief, consistent with MOR agonist class): morphine, heroin, oxycodone, hydrocodone, methadone, and all μ-opioid agonists.

### Dependence/Reward Mechanism

The mesolimbic pathway described in the brief (VTA → nucleus accumbens dopamine via MOR-mediated disinhibition of dopaminergic neurons) is the established opioid reward mechanism [Ref 5 general MOR pharmacology context]. Fentanyl's high efficacy and rapid blood-brain equilibration (4.7–6.6 min) [Ref 1] are consistent with the rate hypothesis of addiction liability — rapid CNS entry → stronger reinforcement.

**Physical/psychological dependence:** Both rated high in the brief. Chen et al. (2025) demonstrated escalation of IV fentanyl self-administration and withdrawal behavior in mice, confirming animal model validity for fentanyl use disorder research.

---

## Interactions

The brief's interaction data are categorized as dangerous or lethal. Evidence basis:

| Interaction | Severity (Brief) | Mechanism | Evidence |
|---|---|---|---|
| Alprazolam | Dangerous | Additive CNS/respiratory depression | Benzodiazepine + opioid combination is a well-documented risk factor for overdose |
| Diazepam | Dangerous | Same as above | Class-level evidence |
| Alcohol | Lethal | Additive CNS/respiratory depression + cardiovascular | Epidemiologically well-documented |
| GHB | Lethal | Additive CNS/respiratory depression; synergistic sedation | Class-level; GHB activates GABA-B receptors |
| GBL | Lethal | Prodrug of GHB; same mechanism | Class-level |
| Ketamine | Lethal | Combined NMDA + MOR effects; additive respiratory depression | Note: ketamine classically stimulates respiration at subanesthetic doses, but combination at high doses poses risk |
| Tramadol | Lethal | Additive opioid respiratory depression; potentially serotonin syndrome via tramadol's norepinephrine-serotonin reuptake inhibition | *No specific published case series or RCT found for fentanyl+tramadol combination — flagged below* |
| Nitrous oxide | Unknown | No published human interaction data found | |
| PCP | Unknown | No published human interaction data found | |

**CYP3A4 inhibitors** (ritonavir, ketoconazole, azole antifungals, certain macrolides): Increase fentanyl exposure significantly [Refs 18, 37]. **CYP3A4 inducers** (rifampin, carbamazepine, St. John's Wort): Expected to reduce fentanyl efficacy [general CYP3A pharmacology].

**Gabapentinoids** (gabapentin, pregabalin): Increase fentanyl potency AND reduce naloxone potency to reverse fentanyl — double-edged risk factor for overdose [Ref 22].

**Xylazine:** Additive cardiorespiratory depression; naloxone insufficient for reversal of xylazine component [Ref 26].

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Notes |
|---|---|---|---|
| United States | Controlled | DEA Schedule II | High abuse potential, accepted medical use; fentanyl-related substances (analogs) classified Schedule I since 2018, TSO extended through September 2025 |
| United Kingdom | Controlled | Class A, Misuse of Drugs Act 1971 | Most severe criminal penalties |
| Canada | Controlled | Schedule I, CDSA (item 16) | Regulated under Narcotic Control Regulations |
| Australia | Controlled | Schedule 8 (Controlled Drug) | Requires additional state/territory notification for prescribing |
| Netherlands | Controlled | Opium Law List I | Equivalent to hardest controlled category |
| EU (member states) | Controlled | Nationally controlled per UN 1961 Convention | All EU member states control fentanyl per Single Convention |
| International | Controlled | Schedule I, UN Single Convention on Narcotic Drugs 1961 | Added in 1964 |

[Sources: Refs 30, 31, 32, 39, 41; web-retrieved]

---

## Clinical Trials

Fentanyl itself is an established pharmaceutical — active clinical trials predominantly test it as comparator/standard care rather than investigational agent. Relevant active/recruiting trials involving fentanyl:

- **NCT06379984** — "Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use" — Phase 2, University of Pennsylvania, recruiting — Tests buprenorphine induction in OUD patients using fentanyl
- **NCT05589181** — "High Dose Buprenorphine Induction in the Emergency Department" — Phase 3, Rutgers — OUD treatment in high-fentanyl-use environment
- **NCT06441604** — "Extended-release Buprenorphine as Novel Low-dose Induction Strategy" — Phase 2, Brigham and Women's Hospital
- Fentanyl inhalant for breakthrough cancer pain: Lin et al. (2024 [Ref 33]) — published multicenter RCT (not trial registry only) confirming efficacy

No trials identified using fentanyl as a novel investigational agent; all relevant trials address fentanyl OUD treatment or fentanyl as an anesthetic comparator.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No community feedback items to analyze.

---

## Gaps & Flags

### Safety-Critical Flags (require human review before publication)

1. **[FLAG — SAFETY-CRITICAL]** Lethal dose "~2 mg in opioid-naïve individuals": This figure appears in the brief's toxicity section but could not be traced to a specific published primary source through this research. The pharmacokinetic and epidemiological literature consistently supports extreme potency of fentanyl but the specific 2 mg threshold needs citation to a published toxicology study or case series before use in generated content.

2. **[FLAG — SAFETY-CRITICAL]** "Delayed re-narcotization from tissue depot redistribution documented in 7.6% of cardiac surgery patients": Mather (1983 [Ref 36]) documents the redistribution phenomenon and delayed respiratory depression as a general clinical concern with high-dose fentanyl, but the specific 7.6% figure and the cardiac surgery source paper were not identified in this literature search. This statistic should be traced to its source before inclusion as a specific claim.

3. **[FLAG — SAFETY-CRITICAL]** "Tolerance to analgesia develops faster than tolerance to respiratory depression": This claim is mechanistically plausible and broadly consistent with the literature, but no single controlled human study directly demonstrating this differential was found. The claim is supported by the receptor reserve/efficacy hypothesis and by incomplete animal data.

4. **[FLAG — INTERACTION]** Tramadol listed as "lethal" interaction: This appears based on additive opioid-mediated respiratory depression and possible serotonin syndrome risk (tramadol inhibits norepinephrine/serotonin reuptake). No published case series or pharmacokinetic interaction study of fentanyl + tramadol specifically was found. The "lethal" classification relies on class-level CNS depressant data and clinical reasoning rather than substance-specific evidence.

5. **[FLAG — INTERACTION]** Ketamine listed as "lethal": At subanesthetic doses, ketamine typically stimulates rather than suppresses respiration, making a "lethal" synergy designation with fentanyl less straightforward than for GABAergic CNS depressants. This interaction severity warrants careful editorial review.

### Data Gaps (no published source found)

6. **SMILES not confirmed via PubChem API:** PubChem returned CID/formula/InChIKey but the SMILES was not retrieved through the API call (which confirmed formula and InChIKey). The standard SMILES from published literature is CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1 and should be verified independently.

7. **Protein binding quantitative value:** Published references consistently cite ~80–85% protein binding (primarily alpha-1-acid glycoprotein) but no specific fentanyl-dedicated controlled study was retrieved through PubMed. The Mather 1983 review [Ref 36] discusses this qualitatively.

8. **Stereochemistry in pharmaceutical preparation:** Fentanyl is marketed as a racemate; no human controlled comparison of enantiomers was found. This is a gap for the pharmacology section.

9. **Neurocognitive impairment from chronic use:** The brief notes "Chronic use produces neurocognitive impairment" — no specific human study documenting this for fentanyl specifically was found. This claim may derive from general chronic opioid literature.

10. **Specific Ki value:** Ki varies widely (0.007–214 nM across all published studies). Most reliable compendium value: human MOR Ki 0.05–5.23 nM (IUPHAR [Ref 40]); IC₅₀ 1.3–10.72 nM. The generation agent should use these ranges rather than a single point estimate.

11. **EU national scheduling specifics:** While all EU member states control fentanyl under the UN 1961 Single Convention, individual national schedule equivalents (e.g., Germany's BtMG, France's classification) were not retrieved.

12. **~80,000 OIRD deaths/year in US:** The brief cites this figure for the epidemiology section. CDC MMWR data shows 36,359 synthetic opioid deaths in 2019 [Ref 29]. The 80,000+ figure is consistent with more recent years (2021–2023) accounting for total opioid-involved deaths including polysubstance, but the specific figure should be tied to an appropriate surveillance year.